

Semi-Annual Management Report of Fund Performance

**PENDER NDI LIFE SCIENCES FUND (VCC) INC. D.B.A.
ADVANTAGE LIFE SCIENCE FUND II**

Six months ended June 30, 2008

This interim annual management report of fund performance contains financial highlights of the Pender NDI Life Sciences Fund (VCC) Inc. (the "Fund"). You may contact us by calling 604-688-6877, by writing us at 1280 - 885 West Georgia Street, Vancouver, BC, V6C 3E8 or by visiting our website at www.bcadvantagefunds.com to request a copy, at no cost to you, of the Fund's financial statements, proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure. You may also obtain a copy of the Fund's financial statements at www.sedar.com.

ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Management Discussion of Fund Performance

Investment Objectives and Strategies

The Fund invests in a diversified portfolio of emerging life science companies with the objective of providing long-term capital appreciation to investors.

The Fund is actively raising new capital and investing this capital in emerging life science companies. Investors receive a 30% refundable tax credit at the time of investment. The companies in which the Fund invests must be eligible businesses in accordance with the B.C. Small Business Venture Capital Act (SBVCA). In general, this means companies based in B.C. that have less than 100 employees and carry on a business activity as specified in the SBVCA.

The Fund's strategy for achieving its objective is to invest in early stage biotech, diagnostic and medical device companies. The Fund invests in companies with superior technology and science, large market opportunities and experienced management. Portfolio companies include private and public companies, as well as companies from the start-up stage through to revenue. Where appropriate, the Fund seeks to build and mentor management in emerging companies to enhance shareholder value.

Risk

An investment in the Fund is highly speculative and carries significant risk. An investment in the Fund is a long-term investment. Over the fiscal year, no material or significant changes occurred that affected the overall risk level associated with the Fund.

The risks of investing in the Fund include a relatively large proportion of private company investments and early-stage concentration. A significant portion of the Fund's investments are in private companies, for which no ready market exists. Valuation of private companies for which no published market exists is subject to inherent uncertainties and the resulting values may differ from values that would have been used had a ready market existed for the investments.

The Fund relies on the allocation of tax credits provided to investors by the administrator of the SBVCA to raise new funds. Issuance of tax credits is discretionary and cannot be guaranteed. The SBVCA administrator has authorized tax credits that will allow the Fund to raise up to an additional \$7 million in each of 2008, 2009 and 2010. Thereafter, the Fund has been provided a rolling three year allocation. If the Fund either cannot raise additional funds or contravenes the SBVCA and has to repay tax credits, it may impair the Fund's ability to carry on business and meet its investment objectives.

There is no market for the Fund's shares, and no market is expected to develop. Investors will not, typically, be able to dispose of their investment other than by way of redemption. In accordance with the SBVCA, investments in portfolio companies must be held for at least five years. As such, an investor's redemption of the Fund's shares is prohibited for at least five years from the date the Fund invests in eligible companies in accordance with the SBVCA. Practically speaking, investors will not be able to redeem their investment for six to seven years from the date they invested in the Fund.

ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Management Discussion of Fund Performance (continued)

Results of Operations

Investment Activity

During the six months ended June 30, 2008, the Fund completed investment of \$1.00 million in 2 new and existing venture investments. As at June 30, 2008, the fair value of the Fund's portfolio investments represented 56% of the net assets of the Fund, while cash and other net assets represented 44% of net assets.

The following table summarizes changes in the composition of the Fund's investment portfolio in comparison to the prior fiscal year:

	June 30 2008	2007
Venture Investments, Cost	\$ 10,329,096	\$ 9,332,571
Venture Investments, Fair Value	8,934,463	7,985,649
Number of Venture Investments:		
Private	3	2
Public	4	4

Of the fair value of the Fund's investments, \$6.41 million or 72% are public companies and \$2.53 million or 28% are private companies. Of the number of the Fund's investments, 43% are private companies and 57% are public companies.

Investment Performance

Over the past six months, the Fund's net asset value per share (NAVPS) declined by \$0.04. The decline in NAVPS was principally due to operating costs incurred by the Fund in excess of investment income and a decrease in the unrealized gains on venture investments (see section entitled "Financial Highlights").

The Fund's management expense ratio (MER) was 7.53% for the six months ended June 30, 2008 as compared to 8.72% for fiscal 2007. The MER for the semi-annual period is an annualized amount. Management expense ratio is based on the total expenses incurred by the Fund inclusive of management fees, all operating costs, and share issuance costs related to marketing and subscription of shares for the stated period.

ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Management Discussion of Fund Performance (continued)

Recent Developments

The Fund is managed by Lions Capital Corp. (the Fund Manager). Consistent with prior periods, the Fund invests in a diversified portfolio of emerging life science companies with the objective of providing long-term capital appreciation to investors. The Fund Manager has maintained the Fund's strategy of investing early in companies with superior technology.

Amalgamation with BC Advantage Funds (VCC) Ltd.:

On August 8, 2008, BC Advantage Funds (VCC) Ltd. ("Advantage") and the Fund were amalgamated into one fund company. This amalgamation was approved by the shareholders of Advantage and the Fund on June 25, 2008. The combined fund company will be comprised of the Advantage Venture Fund, the Advantage Life Science Fund I and the Advantage Life Science Fund II. Advantage and the Fund are both VCC fund companies managed by the Fund Manager. The amalgamation will streamline operations and reduce or eliminate certain operating costs for both funds. This is expected to reduce the management expense ratio of all funds and increase their net asset values, thereby resulting in greater returns to investors. For additional information, please see the Joint Information Circular dated May 22, 2008.

Accounting Policy Changes:

The Canadian Institute of Chartered Accountants ("CICA") has issued Handbook Section 3855, *Financial Instruments - Recognition and Measurement* (S3855) which applies to fiscal years beginning on or after October 1, 2006. The adoption of S3855 impacts the calculation of the net asset value of the Fund for financial reporting purposes because it requires publicly-traded investments to be valued using bid quotations rather than the last sale prices as was the accounting policy of the Funds prior to January 1, 2007.

S3855 also requires that transaction costs, such as brokerage commissions, incurred in the purchase and sale of securities by the Fund, be charged to income from operations in the period incurred. There is no impact on net assets or results of operations of the Fund as a result of this change in accounting policy.

The CICA has also issued Section 3862, Financial Instruments – Disclosures, Section 3863, Financial Instruments – Presentation, and Section 1535, Capital Disclosures.

Section 3862, Financial Instruments – Disclosures and Section 3863, Financial Instruments enhance existing disclosure and presentation of the nature and scope of the risks associated with financial instruments as well as the way these risks are managed. These standards were adopted by the Fund effective January 1, 2008 and have no impact on the recognition or measurement of financial instruments.

Section 1535, Capital Disclosures, requires the disclosure of both qualitative and quantitative information that provides users of financial statements with information to evaluate the entity's objectives, policies, and processes for managing capital. This standard was adopted by the Fund effective January 1, 2008 and has no impact on the recognition or measurement of any financial statement items.

ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Management Discussion of Fund Performance (continued)**Related party transactions**

In accordance with the management agreement between the Fund and the Fund Manager, the Fund Manager receives management fees equal to 2.75% of the net asset value of the Fund, calculated and paid monthly. Also in accordance with the management agreement, separate from the management fee, the Fund reimburses the Fund Manager for expenses incurred by the Fund Manager in connection with its obligations pursuant to the management agreement. The Fund Manager may also earn an equity participation amount based on the realized gains and cumulative performance of the Fund. To date, no equity participation amount has been earned by the Fund Manager.

Related party transactions are disclosed in note 8 of the Fund's financial statements for the six months ended June 30, 2008.

Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the past five years. This information is derived from the Fund's unaudited semi-annual and audited annual financial statements. The Fund commenced operations on July 4, 2003.

The Fund's Net Asset Value per Share⁽²⁾

	June 30 2008	2007	2006	2005	2004
Net asset value, beginning of year	6.28	\$ 7.32	\$ 8.78	\$ 7.76	\$ (55.44)
Net asset value, on inception	-	-	-	-	-
Increase (decrease) from operations:					
Total revenue	0.03	0.10	0.15	0.14	-
Total expenses	(0.16)	(0.44)	(0.59)	(0.84)	(6.41)
Realized gain (loss) for the period	-	(0.78)	-	-	-
Unrealized gain (loss) for the period	(0.02)	(0.13)	(1.14)	0.56	-
Total increase (decrease) from operations ⁽¹⁾	(0.15)	(1.25)	(1.58)	(0.14)	(6.41)
Net asset value, end of period ⁽¹⁾	\$ 6.24	\$ 6.28	\$ 7.32	\$ 8.78	\$ 7.76

⁽¹⁾ Net asset value is based on the actual number of shares outstanding as at December 31 in the year shown or June 30, 2008. The increase/decrease from operations is based on the weighted average number of shares outstanding over the financial period.

⁽²⁾ Net asset value per share is presented in accordance with Canadian generally accepted accounting principles (GAAP). Subscriptions and redemptions of common shares of the Fund are transacted at the Pricing Net Asset Value per Share of the Fund. The Pricing Net Asset Value per Share, which is a non-GAAP measure, is described in detail in the Fund's prospectus and is reconciled in note 6(c) of the Fund's financial statements for the six months ended June 30, 2008.

ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Financial Highlights (continued)

Ratios and Supplemental Data

	June 30 2008	2007	2006	2005	2004
Net asset value (000's) ⁽¹⁾	\$ 16,029	\$ 11,506	\$ 9,749	\$ 8,552	\$ 1,610
Number of shares outstanding ⁽¹⁾	2,571,101	1,831,940	1,330,943	973,598	207,521
MER ⁽²⁾	7.53%	8.72%	9.81%	18.66%	n/a

⁽¹⁾ This information is provided as at December 31 of the year shown or June 30, 2008.

⁽²⁾ Management expense ratio is based on the total expenses incurred by the Fund inclusive of management fees, all operating costs and share issuance costs related to marketing and subscription of shares for the stated year, but excluding income taxes, and is expressed as an annualized percentage of the weighted average net assets during the year.

Portfolio turnover information has not been provided as the Fund invests in venture stage companies which, on average, are held for five to seven years. Similarly, a trading expense ratio has not been provided as the Fund neither engages in active trading, nor purchases securities in the secondary market.

Management Fees

The Fund pays management fees of 2.75% of the net asset value of the Fund, calculated and paid monthly. In consideration for these management fees, the Fund Manager provides day to day management over the Fund and the Fund's venture investment portfolio, including sourcing and administration of all venture investments. The Fund Manager may also earn an equity participation amount based on realized gains and cumulative performance of the Fund. Additional information regarding equity participation is disclosed in note 4 of the Fund's financial statements for the six months ended June 30, 2008.

Past Performance

The Fund's returns are not guaranteed, the values of its shares change frequently and past performance may not be repeated nor can it be used as an indicator of future performance.

Year by Year Returns

The chart below reflects the Fund's annual performance from January 1, 2004 to June 30, 2008, and illustrates how the Fund's performance has changed from year to year. The chart shows in percentage terms how an investment made on the first day of each fiscal year would have increased or decreased by the last day of each period.


ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Past Performance (continued)

Year by Year Returns (continued)



Summary of Investment Portfolio

The following tables summarize the Fund's investment portfolio as at June 30, 2008. This is a summary only and may change due to portfolio activity in the Fund. A quarterly update is available on request.

	Fair value	Percentage of total net assets
Private companies	\$ 2,527,924	16%
Public companies	6,406,539	40
Total Venture Investments	8,934,463	56
Cash and Cash Equivalents and Restricted Cash	7,305,497	46
Net Other Assets less Liabilities	(211,062)	-2
Net Asset Value at June 30, 2008	\$ 16,028,898	100%

PENDER NDI LIFE SCIENCES FUND (VCC) INC. D.B.A.

ADVANTAGE LIFE SCIENCE FUND II

Annual Management Report of Fund Performance

Six months ended June 30, 2008

Summary of Investment Portfolio (continued)

	Percentage of total net assets
Public:	
Allon Therapeutics Inc.	18%
Chromos Molecular Systems Inc.	-
Medical Ventures Corp.	2
Protox Therapeutics Inc.	20
Private:	
Inimex Pharmaceuticals Inc.	3
Methylation Sciences Inc.	1
NeuroMed Technologies Ltd.	12
<hr/> Total Venture Investments	<hr/> 56%